As previously disclosed in our Current Report on Form 8-K filed with the Securities and Exchange Commission on May 1, 2026, on April 27, 2026, Elizabeth H.Z. Thompson, Ph.D., Executive Vice President, Head of Research and Development of ...
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
This Stipulation and Agreement of Settlement (the “Stipulation”) dated July 9, 2026, is entered into by and among the following Parties (defined herein) by and through their respective counsel:
